Scholar Rock Holding (SRRK) Receivables (2019)
Scholar Rock Holding's quarterly Receivables came in at $25.0 million in Q4 2019.
Scholar Rock Holding has reported Receivables for 1 years, with the latest figure at $25.0 million in Q4 2019.
- For the quarter ending Q4 2019, Receivables changed N/A year-over-year to $25.0 million; the trailing twelve-month figure through Dec 2019 stood at $25.0 million (changed N/A YoY), and the FY2019 full-year result was $25.0 million, changed N/A from the prior year.
- Receivables for Q4 2019 stood at $25.0 million.
- The five-year high for Receivables was $25.0 million in Q4 2019, with the low at $25.0 million in Q4 2019.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Receivables (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | 13.10 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | 4.15 Mn |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 2.00 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 5.73 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 883.96 Mn |
| 10 | Scholar Rock Holding | 500.61 Mn | 20.67 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2019 | 25.00 Mn |